Susquehanna International Group
SRNE

Susquehanna International Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Susquehanna International Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-488,100
Closed -$434K – 14119
2022
Q4 		$434K Sell
488,100
-612,900
-56% -$813K ﹤0.01% 8233
2022
Q3 		$1.73M Sell
1,101,000
-30,200
-3% -$68.5K ﹤0.01% 5243
2022
Q2 		$2.27M Buy
1,131,200
+26,000
+2% +$45K ﹤0.01% 4645
2022
Q1 		$2.58M Buy
1,105,200
+14,900
+1% +$46.5K ﹤0.01% 4915
2021
Q4 		$5.07M Buy
1,090,300
+204,400
+23% +$1.27M ﹤0.01% 3713
2021
Q3 		$6.76M Sell
885,900
-51,200
-5% -$434K ﹤0.01% 3462
2021
Q2 		$9.08M Sell
937,100
-462,900
-33% -$3.69M ﹤0.01% 3068
2021
Q1 		$11.6M Sell
1,400,000
-634,300
-31% -$6.7M ﹤0.01% 2552
2020
Q4 		$13.9M Buy
2,034,300
+57,500
+3% +$462K ﹤0.01% 2115
2020
Q3 		$22M Buy
1,976,800
+746,100
+61% +$6.83M ﹤0.01% 1403
2020
Q2 		$7.73M Buy
1,230,700
+973,000
+378% +$3.73M ﹤0.01% 2444
2020
Q1 		$474K Buy
257,700
+23,900
+10% +$68.8K ﹤0.01% 7061
2019
Q4 		$790K Buy
233,800
+56,400
+32% +$134K ﹤0.01% 5986
2019
Q3 		$380K Buy
177,400
+29,800
+20% +$69.5K ﹤0.01% 7844
2019
Q2 		$394K Sell
147,600
-67,100
-31% -$241K ﹤0.01% 7766
2019
Q1 		$1.02M Buy
214,700
+171,400
+396% +$450K ﹤0.01% 5013
2018
Q4 		$104K Sell
43,300
-54,500
-56% -$178K ﹤0.01% 8204
2018
Q3 		$430K Sell
97,800
-149,600
-60% -$829K ﹤0.01% 6810
2018
Q2 		$1.78M Buy
247,400
+38,300
+18% +$261K ﹤0.01% 4208
2018
Q1 		$1.08M Buy
+209,100
New +$1.49M ﹤0.01% 5074
2016
Q4 		– Sell
-22,200
Closed -$172K – 10345
2016
Q3 		$172K Buy
+22,200
New +$149K ﹤0.01% 7692
2016
Q2 		– Sell
-15,200
Closed -$82K – 9537
2016
Q1 		$82K Sell
15,200
-9,500
-38% -$55.2K ﹤0.01% 8509
2015
Q4 		$215K Sell
24,700
-37,900
-61% -$320K ﹤0.01% 8305
2015
Q3 		$525K Buy
62,600
+32,900
+111% +$524K ﹤0.01% 7022
2015
Q2 		$523K Sell
29,700
-32,800
-52% -$421K ﹤0.01% 7557
2015
Q1 		$723K Buy
+62,500
New +$723K ﹤0.01% 6392

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Susquehanna International Group's SRNE Position: Q1 2023 in Review

Susquehanna International Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 1,689,671 shares — an estimated $1.5M sold.

Susquehanna International Group first reported a position in SRNE in Q4 2013 and held it in 29 quarters. The position peaked at $11.7M in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Susquehanna International Group reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Susquehanna International Group sold 1,689,671 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $1.5M.
  • Susquehanna International Group first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 29 quarters.
  • Susquehanna International Group's Sorrento Therapeutics, Inc. position peaked at $11.7M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.